Skip to main content

Table 1 Baseline characteristics of the patients

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Characteristics

Number (proportion,%)

Characteristics

Number (proportion,%)

Sex

 

Hemihepatic HCCc

 

Male

52 (96.3)

Yes

30 (55.6)

Female

2 (3.7)

No

24 (44.4)

Age (years)

 

Distant metastasis

 

≥ 55

18 (33.3)

Yes

14 (25.9)

< 55

36 (66.7)

No

40 (74.1)

Hepatitis B

 

PVTTd

 

Yes

52 (96.3)

Type III

44 (81.5)

No

2 (3.7)

Type IV

10 (18.5)

AFPa ( ng/ml)

 

Tumor diameter

 

≥400

29 (53.7)

> 10 cm

27 (50.0)

<400

25 (46.3)

≤ 10 cm

27 (50.0)

Child-Pugh grade

 

Number of tumors

 

A

42 (77.8)

Single

5 (9.3)

B

12 (22.2)

Multiple

49 (90.7)

ECOG PSb

 

Previous treatment

 

0/1

42 (77.8)

Yes

14 (25.9)

2

12 (22.2)

No

40 (70.5)

Hepatic arterioportal fistulas

 

Postoperative treatment

 

Yes

34 (73.0)

Yes

36 (66.7)

No

20 (37.0)

No

18 (33.3)

  1. aAFP alpha fetoprotein
  2. bECOG PS Cooperative Oncology Group performance status
  3. cHCC hepatocellular carcinoma
  4. dPVTT portal vein tumor thrombosis